Citi lowered the firm’s price target on Abbott to $122 from $130 and keeps a Buy rating on the shares. In a note previewing the Q3 earnings reports, the analyst says that in a short three months, medical technical investing has moved from excitement over recovering procedures and an improving macro environment to fear about the potential impact of GLP-1s and anti-corruption policies in China. When concerns over currency moves and the consumer are added, “it is a recipe for a tough stock environment…but this is where the opportunities can be had,” the analyst tells investors in a research note. Citi’s top picks are Boston Scientific (BSX), DexCom (DXCM) and Stryker (SYK).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABT:
- Abbott’s analysis should ‘calm fears’ about GLP-1 impact on Libre, says TD Cowen
- Abbott says FreeStyle Libre users also on GLP-1 therapy up ‘significantly’
- Abbott Completes Acquisition of Bigfoot Biomedical
- Abbott completes acquisition of Bigfoot Biomedical
- Abbott Declares 399th Consecutive Quarterly Dividend